Skip to main content
. 2021 Nov 5;52(1):29–38. doi: 10.1093/jjco/hyab170

Table 3.

Serious adverse events (any grade) occurring in ≥5% of patients

Serious AE, n (%) Venetoclax-azacitidine (n = 24) Placebo-azacitidine (n = 13)
Any 16 (66.7) 4 (30.8)
Febrile neutropenia 10 (41.7) 0
Neutropenia 4 (16.7) 0
Leukopenia 2 (8.3) 0
Pneumonia 3 (12.5) 1 (7.7)

Abbreviation:AE, adverse event.